The International Symposium on Pediatric Neuro-Oncology (ISPNO 2026) timeline spans essential administrative and scientific milestones, including abstract submission windows, peer review periods, early-bird registration cutoffs, and multi-day conference sessions. Tracking this schedule ensures clinicians, researchers, and allied health professionals meet crucial deadlines for research presentation, travel grant applications, and event registration.
Overview of ISPNO 2026 and Event Governance
The International Symposium on Pediatric Neuro-Oncology (ISPNO) is the premier global assembly dedicated exclusively to pediatric brain and spinal cord tumor research, clinical care, and therapeutic innovation. Held biennially, ISPNO convenes thousands of pediatric neuro-oncologists, neurosurgeons, radiation oncologists, neuropathologists, neuroradiologists, basic scientists, oncology nurses, and patient advocates from around the world.
The event operates under a rotating international governance model, bringing together major regional societies including the Society for Neuro-Oncology (SNO), the European Association of Neuro-Oncology (EANO), and the Asian Society for Neuro-Oncology (ASNO), alongside regional host committees. The multi-day scientific assembly serves as the primary platform for announcing groundbreaking clinical trial results, novel molecular classifications, and advancements in surgical and radiotherapeutic techniques.
Because ISPNO operates on a tight, synchronized international schedule, understanding the operational timeline is vital for all delegates. For presenting authors, missing an abstract submission window or registration confirmation deadline can prevent research from being included in the published program or official conference proceedings. For international attendees, following the schedule allows sufficient time for visa processing, travel funding allocation, and institutional leave approvals.
Master ISPNO 2026 Milestone Timeline
Planning for participation in ISPNO 2026 requires monitoring several parallel tracks, including abstract management, grant applications, delegate registration, and program execution. The following schedule outlines the core milestone windows across the conference lifecycle.
| Phase / Milestone | Timeframe / Schedule Window | Key Action Required | Primary Target Group |
|---|---|---|---|
| Call for Abstracts Opens | Late Fall (Pre-Conference Year) | System opens for submitting scientific abstracts, trial updates, and case reports | Clinical researchers, laboratory scientists, allied health professionals |
| Abstract Submission Deadline | Early Q1 (Conference Year) | Finalize and submit structured abstracts before hard portal closure | Presenting authors and investigative teams |
| Travel Grant Application Window | Early Q1 (Conference Year) | Submit financial aid requests concurrently with abstract submission | Trainees, fellows, early-career researchers, delegates from LMICs |
| Abstract Acceptance Notifications | Mid Spring (Conference Year) | Review acceptance decisions (Oral, Mini-Oral, Poster) and confirm presentation intent | Abstract submitting authors |
| Early-Bird Registration Deadline | Mid-to-Late Spring (Conference Year) | Complete registration to lock in lower delegate fee tiers | All delegates, faculty, and attendees |
| Late-Breaking Abstract Window | Spring (Conference Year) | Submit high-impact late-breaking clinical trial data meeting strict eligibility criteria | Principal investigators of major clinical trials |
| Pre-Conference Educational Days | Day 0 (Opening Week) | Attend targeted pre-symposium masterclasses, nursing tracks, and working groups | Specialized practitioners, trainees, nurses, advocates |
| Main Scientific Symposium | Days 1–4 (Opening Week) | Attend plenary lectures, scientific sessions, poster discussions, and corporate symposia | All registered delegates |
Deep-Dive into Key Timeline Phases
Phase 1: Abstract Submission and Peer Review Window
The scientific abstract submission phase is the first major milestone of the ISPNO 2026 timeline. Authors must prepare structured abstracts detailing original, unpublished research across pediatric neuro-oncology disciplines.
Submissions are typically grouped into distinct scientific tracks, including:
- Basic and Translational Science: Tumor biology, genomics, epigenetics, tumor microenvironment, and novel target identification.
- Clinical Trials and Therapeutics: Phase I–III trial outcomes, investigational drug studies, immunotherapy, and re-irradiation protocols.
- Diagnostics and Imaging: Molecular neuropathology, liquid biopsy, advanced MRI techniques, and PET imaging.
- Surgical and Local Therapies: Intraoperative imaging, fluorescence-guided resection, proton therapy, and stereotactic radiosurgery.
- Nursing, Allied Health, and Survivorship: Late effects, neuro-cognition, rehabilitation, palliative care, and quality-of-life measures.
Once the deadline closes, every abstract undergoes double-blind peer review by an international committee of topic specialists. Reviewers evaluate submissions based on scientific rigor, originality, methodological soundness, and clinical relevance. Authors receive notifications classifying their accepted work as an Oral Platform Presentation, a Mini-Oral Presentation, or a Scientific Poster Presentation.
- Abstract Window Opens
- Abstract Submission Deadline
- Travel Award Deadline
- Peer Review Period
- Acceptance Notifications
Phase 2: Travel Grants and Award Applications
To support diverse international participation, the ISPNO 2026 committee offers competitive travel awards and bursaries. These grants are specifically designed for:
- Medical trainees, residents, fellows, and post-doctoral researchers.
- Investigators within five years of completing their primary training (early-career researchers).
- Delegates actively practicing in low- and middle-income countries (LMICs).
Applications for financial support must be submitted simultaneously with scientific abstracts. Late applications are generally not accepted. Grant decisions are announced alongside abstract acceptance notifications, allowing recipients to arrange institutional travel permissions and visa documentation promptly.
Phase 3: Registration Waves and Accommodation Booking
Registration for ISPNO 2026 progresses through distinct pricing tiers: Early-Bird Registration, Standard Registration, and On-Site Registration.
- Early-Bird Tier: Offers substantial savings for early registrants. Presenting authors must complete registration during this window to ensure their abstract remains in the official scientific program and published abstract journal supplement.
- Member Discounts: Reduced registration fees are available to active members of collaborating organizations such as SNO, EANO, or local host pediatric oncology societies.
- Housing Blocks: Discounted room blocks at official conference hotels open alongside registration. Delegates should book accommodations early, as preferred proximity to the main convention hall fills up quickly.
Pre-Conference Workshops and Special Focus Days
Before the main scientific program begins, the ISPNO 2026 schedule includes targeted workshops and educational symposia on Day 0. These pre-conference sessions allow participants to gain practical training and participate in focused multidisciplinary panels.
Nursing and Allied Health Symposium
This dedicated full-day program addresses the specialized care requirements of pediatric neuro-oncology patients. Topics include symptom management, complex neuro-rehabilitation, family-centered communication, transition to survivorship, and pediatric palliative care. It provides vital continuing education for nurse practitioners, clinical nurse specialists, social workers, and psychologists.
Neuropathology and Integrated Molecular Diagnostics Masterclass
Given the evolution of the WHO Classification of Tumors of the Central Nervous System, this masterclass focuses on integrating histopathological evaluation with advanced molecular diagnostics. Workshop leaders guide attendees through DNA methylation profiling, next-generation sequencing panel interpretation, and practical diagnostic workflows for challenging pediatric CNS tumors, such as diffuse midline gliomas and embryonal neoplasms.
Surgical and Radiotherapeutic Innovation Workshops
Designed for pediatric neurosurgeons and radiation oncologists, these sessions cover emerging surgical techniques and radiotherapy technologies. Content includes intraoperative MRI utilization, neuro-endoscopy, fluorescence-guided surgery (5-ALA), proton beam therapy planning, intraoperative radiotherapy (IORT), and re-irradiation strategies for recurrent diseases.
Adolescent and Young Adult (AYA) Working Group Sessions
Addressing the unique clinical, biological, and psychosocial needs of AYA patients with brain tumors, these sessions focus on clinical trial enrollment, fertility preservation, survivorship models, and targeted therapies for young adult neuro-oncology.
Main Scientific Symposium Schedule and Daily Structure
The core scientific program spans four consecutive days, structured to highlight major research domains, encourage cross-disciplinary discussion, and accommodate global networking.
| Day 1 | Day 2 | Day 3 | Day 4 |
|---|---|---|---|
| Keynote Plenary | Keynote Plenary | Keynote Plenary | Keynote Plenary |
| Molecular Targets | High-Grade Glioma | Low-Grade Glioma | Radiotherapy Innovation |
| Medulloblastoma | Embryonal Tumors | Targeted Therapies | Survivorship & Quality |
| Poster Session I | Poster Session II | Poster Session III | Closing & Future ISPNO |
Day 1: Opening Ceremonies, Molecular Biology, and Medulloblastoma
- Morning: Official opening remarks by conference chairs and host organization leadership, followed by high-level keynote presentations on global trends in pediatric neuro-oncology.
- Mid-Day Sessions: Scientific tracks focusing on tumor genomics, epigenetic driving mechanisms, and molecularly defined sub-entities of medulloblastoma (WNT, SHH, Group 3, Group 4).
- Afternoon Sessions: Clinical trial outcomes for newly diagnosed and recurrent medulloblastoma, novel drug delivery strategies (such as convection-enhanced delivery), and surgical resection limits.
- Evening: Scientific Poster Session I and Welcome Reception.
Day 2: High-Grade Gliomas, Ependymoma, and Surgical Advances
- Morning: Plenary lectures dedicated to diffuse high-grade gliomas, including H3 K27-altered diffuse midline gliomas (DMG) and H3 G34-mutant diffuse hemisphere gliomas.
- Mid-Day Sessions: Therapeutic strategies targeting histone mutations, oncogenic fusion drivers, and immune microenvironment modulation. Secondary tracks focus on ependymoma subtyping (PFA, PFB, ZFTA fusion, YAP1 fusion) and therapeutic resistance.
- Afternoon Sessions: Pediatric neurosurgery symposia covering minimally invasive approaches, awake craniotomies in pediatric patients, and surgical management of deep-seated brainstem lesions.
- Evening: Scientific Poster Session II and specialized networking discussions.
Day 3: Low-Grade Gliomas, Targeted Therapies, and Immunotherapy
- Morning: Plenary focused on pediatric low-grade gliomas (PLGG) and the shift toward precision targeted treatments.
- Mid-Day Sessions: Detailed analysis of BRAF-altered tumors (BRAF V600E mutations, KIAA1549-BRAF fusions), MEK inhibitors, second-generation BRAF inhibitors, and FGFR alterations. Dedicated tracks examine tumor predisposition syndromes (NF1, NF2, Tuberous Sclerosis, Li-Fraumeni syndrome).
- Afternoon Sessions: Immunotherapy innovations, including CAR-T cell therapy for CNS malignancies, checkpoint inhibitors, therapeutic vaccines, and viral therapies.
- Evening: ISPNO Gala Dinner and formal networking event.
Day 4: Radiation Oncology, Late Effects, Survivorship, and Closing Remarks
- Morning: Advanced radiation oncology sessions comparing intensity-modulated proton therapy (IMPT), photon stereotactic radiosurgery, and FLASH radiotherapy.
- Mid-Day Sessions: Comprehensive survivorship presentations examining long-term endocrine, neuro-cognitive, vascular, and secondary malignancy risks in pediatric tumor survivors. Interventions to mitigate treatment toxicity are emphasized.
- Afternoon: Presentation of Scientific Awards (Young Investigator Award, Best Abstract Awards), announcement of the host city for the next ISPNO, and formal closing remarks.
Guidelines for Abstract Preparation and Submission
Presenting high-quality research at ISPNO 2026 requires adherence to standardized submission parameters. Authors should follow these best practices when preparing their submissions:
- Structuring the Text: Most abstracts require a strict layout divided into Background/Objectives, Methods, Results, and Conclusions. Ensure that numbers, statistical parameters ($p$-values, confidence intervals), and sample sizes are explicitly stated in the results section.
- Word Count Limits: The text body is typically restricted to 250 to 300 words. Title, author list, and institutional affiliations are processed separately within the online submission engine.
- Ethical Approvals and Trial Registration: Research involving human subjects or patient tissue samples must explicitly reference Institutional Review Board (IRB) or Ethics Committee approval. Prospective clinical trials must provide their registry identifier (such as ClinicalTrials.gov or EudraCT numbers).
- Financial Disclosures: Authors must complete conflict of interest disclosures for all co-authors at the time of submission to maintain accreditation integrity for CME activities.
Visa, Travel, and Logistics Preparation
Attending an international medical congress requires managing administrative timelines well in advance of the event dates. International delegates should align their travel preparations with the following lead-time recommendations:
- Conference - 6 Months: Apply for Entry Visa & Confirm Passport Validity
- Conference - 4 Months: Complete Early-Bird Registration & Hotel Booking
- Conference - 2 Months: Finalize Air Travel & Presentation Slides
- Conference Week: On-Site Badge Pick-up & Program Attendance
- Visa Applications: Delegates requiring an entry visa for the host country should request an official Letter of Invitation during the registration process. Visa applications should be submitted at least 4 to 6 months before departure due to potential embassy processing delays.
- Passport Validity: Ensure your passport has at least six months of validity remaining beyond your planned return date, along with sufficient blank visa pages.
- Travel Insurance: Obtain comprehensive international travel insurance covering medical emergencies, trip cancellations, and travel delays.
Common Timeline Pitfalls and How to Avoid Them
| Pitfall | Operational Impact | Prevention Strategy |
|---|---|---|
| Last-Minute Abstract Submission | Server overload, formatting glitches, missed cutoff | Complete and review the abstract submission at least 48 hours before the deadline. |
| Delayed Visa Processing | Inability to travel despite accepted abstract | Apply for an invitation letter immediately upon abstract acceptance or early registration. |
| Missing the Early-Bird Window | Incurring higher registration fees, potential cancellation of unconfirmed abstracts | Set calendar reminders for registration cutoff dates and process institutional payments promptly. |
| Oversights in Co-Author Approvals | Abstract retraction or authorship disputes | Circulate the final abstract draft to all co-authors for sign-off well before submission. |
| Unregistered Pre-Conference Workshops | Missing specialized masterclasses due to cap limits | Select optional workshops during primary registration rather than trying to add them on-site. |
Frequently Asked Questions
What is the official language of ISPNO 2026?
The official language for all written abstracts, oral presentations, scientific posters, and program materials at ISPNO 2026 is English. Simultaneous translation services are generally not provided.
Can an abstract be submitted if the data is not fully analyzed?
Abstracts should contain definitive, measurable data and conclusions. Submissions that rely on statements such as "results will be discussed" are generally rejected during peer review. However, trial-in-progress protocols with initial safety cohorts or late-breaking clinical trial submissions may be accommodated under specific platform guidelines.
How are late-breaking abstracts handled for ISPNO 2026?
Late-breaking abstract windows are reserved strictly for high-impact, late-phase clinical trial results or groundbreaking laboratory breakthroughs achieved after the main abstract deadline. Preliminary or small-scale studies are not eligible for late-breaking consideration.
Are presentations archived for digital viewing after the conference?
Most ISPNO events offer an on-demand virtual library for registered attendees, containing slide presentations, recorded oral sessions, and electronic posters (e-posters). Access parameters and release dates are detailed closer to the conference start date.
How do delegates claim Continuing Medical Education (CME) credits?
Registered attendees receive a link to an online CME evaluation form following the conclusion of the symposium. Completing the session evaluations and overall conference feedback generates an official CME certificate detailing accredited credit hours based on attended sessions.
Practical Recommendations for Intending Delegates
- Establish an Internal Timeline: Work backward from the abstract submission deadline. Set internal drafts due 2 to 3 weeks early to allow adequate co-author review, statistical validation, and institutional approval.
- Coordinate Institutional Funding Early: Submit travel grant applications and secure departmental travel authorizations during the initial phase of the conference lifecycle to ensure funding is locked in before registration prices increase.
- Monitor Official Communications: Bookmark the official ISPNO 2026 website and subscribe to electronic updates from the host society to stay informed about deadline extensions, program updates, and logistical announcements.
- Prepare Digital Poster Assets Early: If your abstract is accepted for a poster presentation, review the dimensions, formatting requirements, and e-poster upload deadlines early to avoid last-minute formatting issues.
